Literature DB >> 6131186

Renal failure associated with intravenous diphosphonates.

H M Bounameaux, J Schifferli, J P Montani, A Jung, F Chatelanat.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6131186     DOI： 10.1016/s0140-6736(83)91465-4

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  38 in total

1.  Nephrotic syndrome after oral bisphosphonate (alendronate) administration in a patient with osteoporosis.

Authors:  M Yilmaz; H Taninmis; E Kara; A Ozagari; A Unsal
Journal:  Osteoporos Int       Date:  2012-01-26       Impact factor: 4.507

Review 2.  Adverse effects of bisphosphonates. A comparative review.

Authors:  S Adami; N Zamberlan
Journal:  Drug Saf       Date:  1996-03       Impact factor: 5.606

Review 3.  Advances in the management of Paget's disease of bone.

Authors:  D J Hosking
Journal:  Drugs       Date:  1990-12       Impact factor: 9.546

Review 4.  Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease.

Authors:  H Fleisch
Journal:  Drugs       Date:  1991-12       Impact factor: 9.546

Review 5.  Comparative clinical pharmacology and therapeutic use of bisphosphonates in metabolic bone diseases.

Authors:  C J Rosen; C R Kessenich
Journal:  Drugs       Date:  1996-04       Impact factor: 9.546

Review 6.  Bisphosphonates and the treatment of bone disease in the elderly.

Authors:  A Johansen; M Stone; F Rawlinson
Journal:  Drugs Aging       Date:  1996-02       Impact factor: 3.923

Review 7.  Drugs used in the treatment of metabolic bone disease. Clinical pharmacology and therapeutic use.

Authors:  S Patel; A R Lyons; D J Hosking
Journal:  Drugs       Date:  1993-10       Impact factor: 9.546

8.  Calcium free hemodialysis: experience in the treatment of 33 patients with severe hypercalcemia.

Authors:  C Camus; C Charasse; I Jouannic-Montier; P Seguin; Y L Tulzo; J Bouget; R Thomas
Journal:  Intensive Care Med       Date:  1996-02       Impact factor: 17.440

9.  Efficacy and safety of ibandronate in the treatment of hypercalcemia of malignancy: a randomized multicentric comparison to pamidronate.

Authors:  M Pecherstorfer; E U Steinhauer; R Rizzoli; M Wetterwald; B Bergström
Journal:  Support Care Cancer       Date:  2003-06-03       Impact factor: 3.603

10.  Measurement of serum [3H]tetracycline kinetics and indices of kidney function facilitate study of the activity and toxic effects of bisphosphonates in bone resorption.

Authors:  G Golomb; Y Eitan; A Hoffman
Journal:  Pharm Res       Date:  1992-08       Impact factor: 4.200
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.